title: A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy.
abstract: Epidermal growth factor receptor (EGFR) is an important therapeutic target in lung cancer. Gefitinib and erlotinib, two reversible EGFR receptor tyrosine kinases inhibitors (TKIs), have been approved for the treatment of patients with metastatic non small-cell lung cancer. Icotinib, which is a selective EGFR-TKI, provides a similar efficacy to gefitinib. The present study aimed to investigate the survival and safety of icotinib in patients with lung adenocarcinoma with a poor performance status (PS). A total of 42 cases of lung adenocarcinoma, including 35 females and 7 males, were enrolled. Icotinib was used as the first-line of treatment due to poor PS of the patient or a more advanced age. Icotinib (125 mg) was orally administered three times per day. The overall response rate and disease control rates were 33.3 and 85.7%, respectively. The median survival time was 13.0 months (95% CI, 5.6-20.4), The median progression-free survival time was 7.0 months, and the 1-year survival rate was 71.4%. A total of 79% of patients had an improved PS following icotinib treatment. Grade 1 to 2 rashes and diarrhea were the most frequent side effects. One patient succumbed during the study due to interstitial pneumonia. In conclusion, this is the first study indicating that patients with lung adenocarcinoma and poor PS may benefit from first-line icotinib therapy, but should be cautious of the occurrence of interstitial lung disease.
authors.affiliation: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Zheng
authors.affiliation: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Guan
authors.initials: G
authors.lastname: Liu
authors.affiliation: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Shengye
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Surgical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Yunli
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Integrated Chinese Traditional Medicine and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Wenlong
authors.initials: W
authors.lastname: Bao
authors.affiliation: Integrated Chinese Traditional Medicine and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Dehou
authors.initials: D
authors.lastname: Deng
authors.affiliation: Department of Surgical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China ; Zhejiang Thoracic Oncology Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Weiming
authors.initials: W
authors.lastname: Mao
authors.affiliation: Integrated Chinese Traditional Medicine and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China.
authors.forename: Meiyu
authors.initials: M
authors.lastname: Fang
keywords: adenocarcinoma; icotinib hydrochloride; non-small cell lung cancer; performance status